Product Technology

Axiogenesis is the world leader in developing and producing stem cell-derived cardiomyocytes, both human and murine (mouse), as well as other cell types. Through genetic modification and selection, Axiogenesis has patented a process for the cell-type specific selection of (heart) cells, allowing for the production of cell cultures that are virtually 100% pure and genetically homogeneous.

Axiogenesis produces induced pluripotent stem (iPS) cell-derived cell types, both human and murine, in addition to murine embryonic stem cell (ESC) derived cells. Mouse iPSC heart muscle cells (Murine cardiomyocytes) were launched in 2008 (Cor.At®) and human iPSC cardiomyocytes (Cor.4U®) were launched in 2012.

Axiogenesis is the market leader in ready-to-use murine stem cell-derived cardiomyocytes and has also produced several other tissue-specific cells using murine embryonic stem cells as the source (skin, endothelial, neuronal, liver etc.).

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10